van Schaik RH - Search Results

1

Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study.

Elens L, Becker ML, Haufroid V, Hofman A, Visser LE, Uitterlinden AG, Stricker BCh, van Schaik RH. Elens L, et al. Among authors: van schaik rh. Pharmacogenet Genomics. 2011 Dec;21(12):861-6. doi: 10.1097/FPC.0b013e32834c6edb. Pharmacogenet Genomics. 2011. PMID: 21946898

2

CYP3A4-V polymorphism detection by PCR-restriction fragment length polymorphism analysis and its allelic frequency among 199 Dutch Caucasians.

van Schaik RH, de Wildt SN, van Iperen NM, Uitterlinden AG, van den Anker JN, Lindemans J. van Schaik RH, et al. Among authors: van iperen nm, van den anker jn. Clin Chem. 2000 Nov;46(11):1834-6. Clin Chem. 2000. PMID: 11067821 No abstract available.

3

The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon.

Visser LE, van Vliet M, van Schaik RH, Kasbergen AA, De Smet PA, Vulto AG, Hofman A, van Duijn CM, Stricker BH. Visser LE, et al. Among authors: van duijn cm, van schaik rh, van vliet m. Pharmacogenetics. 2004 Jan;14(1):27-33. doi: 10.1097/00008571-200401000-00003. Pharmacogenetics. 2004. PMID: 15128048

4

The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon.

Visser LE, van Schaik RH, van Vliet M, Trienekens PH, De Smet PA, Vulto AG, Hofman A, van Duijn CM, Stricker BH. Visser LE, et al. Among authors: van duijn cm, van schaik rh, van vliet m. Thromb Haemost. 2004 Jul;92(1):61-6. doi: 10.1160/TH03-12-0741. Thromb Haemost. 2004. PMID: 15213846

5

Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes.

Hesselink DA, van Gelder T, van Schaik RH, Balk AH, van der Heiden IP, van Dam T, van der Werf M, Weimar W, Mathot RA. Hesselink DA, et al. Among authors: van dam t, van gelder t, van der werf m, van schaik rh, van der heiden ip. Clin Pharmacol Ther. 2004 Dec;76(6):545-56. doi: 10.1016/j.clpt.2004.08.022. Clin Pharmacol Ther. 2004. PMID: 15592326

6

Allelic variants of cytochrome P450 2C9 modify the interaction between nonsteroidal anti-inflammatory drugs and coumarin anticoagulants.

Visser LE, van Schaik RH, van Vliet M, Trienekens PH, De Smet PA, Vulto AG, Hofman A, van Duijn CM, Stricker BH. Visser LE, et al. Among authors: van duijn cm, van schaik rh, van vliet m. Clin Pharmacol Ther. 2005 Jun;77(6):479-85. doi: 10.1016/j.clpt.2005.02.009. Clin Pharmacol Ther. 2005. PMID: 15961979

7

A common polymorphism in the CYP3A7 gene is associated with a nearly 50% reduction in serum dehydroepiandrosterone sulfate levels.

Smit P, van Schaik RH, van der Werf M, van den Beld AW, Koper JW, Lindemans J, Pols HA, Brinkmann AO, de Jong FH, Lamberts SW. Smit P, et al. Among authors: van der werf m, van den beld aw, van schaik rh. J Clin Endocrinol Metab. 2005 Sep;90(9):5313-6. doi: 10.1210/jc.2005-0307. Epub 2005 Jun 28. J Clin Endocrinol Metab. 2005. PMID: 15985487

8

A new CYP3A5 variant, CYP3A5*11, is shown to be defective in nifedipine metabolism in a recombinant cDNA expression system.

Lee SJ, van der Heiden IP, Goldstein JA, van Schaik RH. Lee SJ, et al. Among authors: van schaik rh, van der heiden ip. Drug Metab Dispos. 2007 Jan;35(1):67-71. doi: 10.1124/dmd.106.012310. Epub 2006 Oct 11. Drug Metab Dispos. 2007. PMID: 17035598 Free PMC article.

9

Effects of the renin-angiotensin system genes and salt sensitivity genes on blood pressure and atherosclerosis in the total population and patients with type 2 diabetes.

Yazdanpanah M, Aulchenko YS, Hofman A, Janssen JA, Sayed-Tabatabaei FA, van Schaik RH, Klungel OH, Stricker BH, Pols HA, Witteman JC, Lamberts SW, Oostra BA, van Duijn CM. Yazdanpanah M, et al. Among authors: van duijn cm, van schaik rh. Diabetes. 2007 Jul;56(7):1905-12. doi: 10.2337/db06-1127. Epub 2007 Apr 19. Diabetes. 2007. PMID: 17446534

10

The risk of myocardial infarction in patients with reduced activity of cytochrome P450 2C9.

Visser LE, van Schaik RH, Jan Danser AH, Hofman A, Witteman JC, van Duijn CM, Uitterlinden AG, Pols HA, Stricker BH. Visser LE, et al. Among authors: van duijn cm, van schaik rh. Pharmacogenet Genomics. 2007 Jul;17(7):473-9. doi: 10.1097/01.fpc.0000236335.57046.c8. Pharmacogenet Genomics. 2007. PMID: 17558303

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

424 results

Search Page

Filters